Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
Association of GI symptoms with health-related quality of life in cancer patients undergoing chemotherapy: a prospective study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Obulapuram Ramadevi, Narapaka Pavan Kumar, Esuru Chindu, Singh Manisha, Dhingra Sameer
Аннотация
PURPOSE: Chemotherapy, a primary cancer treatment, often leads to debilitating gastrointestinal (GI) side effects, significantly impacting health-related quality of life (HRQoL). This study investigates the prevalence and impact of gastrointestinal (GI) symptoms on HRQoL in cancer patients undergoing chemotherapy in Bihar, India.
METHODS: This prospective observational study enrolled 246 chemotherapy patients (≥ 18 years) over 9 months. GI symptoms and HRQoL were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) and Short Form-36 (SF-36) questionnaires. Data analysis employed SPSS v.27, with t-tests determining significant associations.
RESULTS: Mild GI symptoms were prevalent (72.8% reported mild pain; 84.6% reported mild heartburn), while severe nausea (81.7%) and diarrhea (56.1%) were notable. A significant correlation existed between symptom severity and HRQoL decline (t = 15.35, p < 0.01). Severe symptoms substantially reduced HRQoL, particularly in pain (from 498.2 to 464.2), heartburn (from 493.6 to 483.4), nausea (from 497.2 to 492.1), diarrhea (from 494.9 to 473.3), and constipation (from 487.8 to 467.7), with declines in QoL scores ranging from 4.6 to 34.0 points across symptom categories, indicating a significant impact on patients' quality of life.
CONCLUSION: GI symptoms significantly impair HRQoL in cancer patients undergoing chemotherapy, affecting physical functioning, emotional well-being, social interactions, energy levels, and overall health. A multidisciplinary approach, incorporating psychological support and social rehabilitation, is crucial for managing symptoms and enhancing patient well-being.
METHODS: This prospective observational study enrolled 246 chemotherapy patients (≥ 18 years) over 9 months. GI symptoms and HRQoL were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) and Short Form-36 (SF-36) questionnaires. Data analysis employed SPSS v.27, with t-tests determining significant associations.
RESULTS: Mild GI symptoms were prevalent (72.8% reported mild pain; 84.6% reported mild heartburn), while severe nausea (81.7%) and diarrhea (56.1%) were notable. A significant correlation existed between symptom severity and HRQoL decline (t = 15.35, p < 0.01). Severe symptoms substantially reduced HRQoL, particularly in pain (from 498.2 to 464.2), heartburn (from 493.6 to 483.4), nausea (from 497.2 to 492.1), diarrhea (from 494.9 to 473.3), and constipation (from 487.8 to 467.7), with declines in QoL scores ranging from 4.6 to 34.0 points across symptom categories, indicating a significant impact on patients' quality of life.
CONCLUSION: GI symptoms significantly impair HRQoL in cancer patients undergoing chemotherapy, affecting physical functioning, emotional well-being, social interactions, energy levels, and overall health. A multidisciplinary approach, incorporating psychological support and social rehabilitation, is crucial for managing symptoms and enhancing patient well-being.